<DOC>
	<DOCNO>NCT00209222</DOCNO>
	<brief_summary>The aim study determine whether alternate course cyclophosphamide , doxorubicin , vincristine , prednisone/dexamethasone , cytarabine , cisplatin ( CHOP/DHAP ) plus rituximab follow total body irradiation [ TBI ] /high dose cytarabine [ ARA-C ] /melphalan-peripheral blood stem cell transplantation ( TAM-PBSCT ) improve time treatment failure compare CHOP plus rituximab follow standard PBSCT ( dexamethasone , carmustine , cytarabine , etoposide , melphalan [ Dexa-BEAM ] /TBI/high dose cyclophosphamide ) patient untreated mantle cell lymphoma .</brief_summary>
	<brief_title>Efficacy R-CHOP v R-CHOP/R-DHAP Untreated MCL</brief_title>
	<detailed_description>Recently , prospective randomize intergroup trial European MCL Network show myeloablative radio-chemotherapy follow autologous stem cell transplantation ( PBSCT ) improve event-free survival ( EFS ) compare interferon alpha maintenance therapy CHOP-like induction . However , CR rate CHOP induction still low ( &lt; 20 % ) . Thus , several study conduct increase CR rate induction therapy improve event-free overall survival . Two recent phase II trial suggest induction regimen contain high dose Ara-C may significantly improve CR rate 80 % . In addition , number study provide evidence humanize anti-CD20 antibody Rituximab may induce significant response relapse MCL . A prospective randomize study GLSG demonstrate combined immuno-chemotherapy ( CHOP plus Rituximab ) induce significantly high response rate CHOP alone . The aim study comparison current standard ( R-CHOP follow myeloablative radio-chemotherapy subsequent blood stem cell transplantation ) new alternate induction regimen contain high dose Ara-C ( R-CHOP/DHAP ) follow high dose ARA-C contain myeloablative radio-chemotherapy PBSCT . This study perform prospective , randomize , open-label multicenter phase III trial . All patient initial randomized standard treatment versus experimental treatment . REFERENCE ARM : The induction therapy consist 6 cycle CHOP chemotherapy combination Rituximab . If mantle cell lymphoma progressive 4 cycle chemotherapy , patient take study . Patients achieve least partial remission 6 cycle R-CHOP proceed intensify consolidation ( Dexa-BEAM ) stem cell collection subsequent myelo-ablative radio-chemotherapy ( TBI/High Dose Cyclophosphamide ) autologous stem cell transplantation EXPERIMENTAL ARM : Initial cytoreductive chemotherapy comprise alternate cycle 3xCHOP 3x DHAP plus Rituximab . Patients progressive disease 2 treatment cycle R-CHOP 2x R-DHAP study . Patients achieve least partial remission 3x CHOP 3x DHAP plus Rituximab proceed stem cell collection . The subsequent myeloablative radio-chemotherapy stem cell transplantation consist radiotherapy ( TBI ) , high dose Ara-C Melphalan . The primary end point study time treatment failure . The time treatment failure define time start initial therapy first failure . A failure define failure initial therapy progression lymphoma death patient . Using data PBSCT group former European mantle cell study baseline proportional hazard model , improvement time treatment failure expect new strategy express reduction relative risk ( rr ) . A risk reduction 52 % would correspond improvement 20 % failure free survival 3 year seem clinical relevant improvement . For work significance level alpha=0.05 power 95 % number event necessary one side fix sample trial 105 . During study time treatment failure monitor use equivalent one-sided triangular sequential test . In order evaluate impact therapy overall survival patient , total follow 12 year study expect .</detailed_description>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven diagnosis mantle cell lymphoma ( World Health Organization [ WHO ] classification ) Clinical stage II IV ( Ann Arbor ) Previously untreated patient Age 18 65 year WHO performance &lt; 2 Measurable disease ( also : patient isolate bone marrow involvement ) Informed consent accord International Conference Harmonisation Technical Requirements Registration Pharmaceuticals Human Use/European Union Good Clinical Practice ( ICH/EU GCP ) national/local regulation Age &gt; 65 year WHO performance status &gt; 2 Known antimurine antibody ( HAMA ) reactivity know hypersensitivity murine antibodies Previous lymphoma therapy radiation , cytostatic drug , antiCD20 antibody interferon Serious disease interfere regular therapy accord study protocol : cardiac ( e.g . manifest heart failure , coronary heart disease , uncontrolled hypertension ) pulmonary ( e.g . chronic lung disease hypoxemia ) endocrine ( e.g . severe , sufficiently control diabetes mellitus ) renal insufficiency ( unless cause lymphoma ) : creatinine &gt; 2x normal value and/or creatinine clearance &lt; 50 ml/min ) impairment liver function ( unless cause lymphoma ) : transaminase &gt; 3x normal bilirubin &gt; 2,0 mg/dl Patients unresolved hepatitis B C infection know HIV infection Prior organ , bone marrow peripheral blood stem cell transplantation Concomitant previous malignancy within last 5 year basal cell skin cancer situ uterine cervix cancer . Pregnancy lactation Any psychological , familiar , sociological , geographical condition potentially hamper compliance study protocol follow schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Lymphoma , Mantle-Cell</keyword>
	<keyword>young patient</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>high dose therapy</keyword>
	<keyword>C04.557.386.480.300.725.500</keyword>
	<keyword>C15.604.515.569.480.300.725.500</keyword>
	<keyword>C20.683.515.761.480.300.725.500</keyword>
</DOC>